Status:
RECRUITING
Autoimmune Endocrine Disease Related Antibodies Before the Start of Immune Checkpoint Inhibitor Therapy
Lead Sponsor:
Laura ICONARU
Conditions:
Autoimmunity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Promising treatments have been added to the oncologist's arsenal in recent years. Treatments that, unlike conventional chemotherapy, do not aim to destroy cancer cells directly, but rather activate th...
Detailed Description
Immune checkpoint inhibitor therapy (ICI) is the current standard of care for many malignancies, due to its unique mechanism of action. These therapies release the brakes of the immune system by targe...
Eligibility Criteria
Inclusion
- All subjects eligible for immune checkpoint therapy at the participating study sites. The cohort will consist of all subjects who consent to participate, and to use their information for future research and publication in a scientific journal.
Exclusion
- Pregnancy
Key Trial Info
Start Date :
November 14 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06993727
Start Date
November 14 2023
End Date
December 1 2027
Last Update
May 29 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
C.H.U. Saint-Pierre
Brussels, Belgium, 1000
2
CHU Brugmann
Brussels, Belgium, 1020
3
HUB - Institut Jules Bordet
Brussels, Belgium, 1070